You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
Omicron病毒全球肆虐 惟本港上市疫苗生物股隨外圍同業捱沽
Omicron新冠變種病毒於全球肆虐,其中美國確診病例創紀錄高,導致美國數以千計學校推遲返校或轉為遠程學習。而美國食品藥物管理局(FDA)授權12至15歲兒童接種輝瑞(PFE.US)和BioNTech(BNTX.US)提供第三劑新冠疫苗,BioNTech股價隔晚(3日)挫10.1%收231.85美元,但輝瑞昨晚逆市挫逾4%收56.65美元;另一隻疫苗股莫德納(MRNA.US)更挫7.5%收235.05美元。 於本港上市疫苗和生物股今天也普遍下挫,尤其是康希諾生物-B(06185.HK)一舉破20天、50天及10天線(167.7-175.4元),最低見159元,現報160元,急挫10.7%。信達生物(01801.HK)連挫兩天屢尋底,今天低見39.7元,創逾年半低,現報40元,續挫9.2%。開拓藥業-B(09939.HK)低見12.12元,現報12.26元,挫8.1% 藍籌藥明生物(02269.HK)繼昨天一舉跌破10天及20天線後,今天進一步低見79.1元,現報81.7元,續挫6.3%;其母企藥明康德(02359.HK)也連挫兩天,股價繼昨天失守10天線後,今天低116.1元,創逾九個月低,現報117.7元,續挫6.1%。 騰盛博藥-B(02137.HK)最低見27.85元,現報28.85元,續挫8.8%。復星醫藥(02196.HK)最低見32.4元,現報32.45元,續跌3.3%。康方生物-B(09926.HK)最低見27.8元,屢創逾一年低,現報28.5元,續跌6.3%;康寧傑瑞製藥-B(09966.HK)低見12.42元,現報12.64元,反覆續跌4.8%。百濟神州(06160.HK)低見152.1元,現報152.3元,續挫4.9%。 此外,歌禮製藥-B(01672.HK)公布全資附屬自主研發治療非酒精性脂肪性肝炎藥物完成美國I期臨床試驗。該股繼昨天急漲32%後,今早進一步升至4.61元創近兩年高遇阻,掉頭低見3.81元,現報4.28元,倒跌1.6%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account